Communiqués Lundbeck Nasdaq Copenhagen

Actions

LUN

DK0061804697

Produits pharmaceutiques

Marché Fermé - Nasdaq Copenhagen 17:20:00 12/08/2026			Varia. 5j.	Varia. 1 janv.
35,45 ^DKK	0,00%		-0,14%	-2,07%

11/08	Moberg Pharma nomme de nouveaux directeurs commercial et médical	MT
23/07	Lundbeck reçoit la désignation " Fast Track » de la FDA pour le Lu AH69593, un agoniste des récepteurs de l'orexine 2 en cours de développement pour la narcolepsie	CI

Communiqués

23/07	Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy	AQ
20/07	Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)	AQ
24/06	Tarek Samad appointed EVP, Head of Research & Development at Lundbeck	AQ
24/06	Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026	AQ
14/06	Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026	AQ
10/06	Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026	AQ
04/06	Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress	AQ
03/06	Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments	AQ
26/05	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine	AQ
19/05	H Lundbeck A/S : Transcript (Transcript)	PU
18/05	Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease	AQ
13/05	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck Q1 2026 FINAL)	PU
12/05	H Lundbeck A/S : Release (Q1 2026 Corporate Release)	PU
12/05	Strong start to 2026: +21% CER revenue growth (+13% CER underlying)	AQ
12/05	Lundbeck raises financial guidance for 2026	AQ
19/04	Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)	AQ
13/04	Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting	AQ
30/03	H Lundbeck A/S : Remuneration Policy 2026 (Remuneration Policy 2026)	PU
18/03	Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office	AQ
18/03	H Lundbeck A/S : Presentation (AGM Presentation 2026)	PU
16/03	Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026	AQ
10/03	Lundbeck appoints Chief AI Officer	AQ
09/03	Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial	AQ
17/02	H Lundbeck A/S : Remuneration Report 2025 (Remuneration Report 2025)	PU
17/02	H Lundbeck A/S : Registration form (Registration form)	PU